0.16
+2.76%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Poxel
Its shares trade on Euronext Paris under the ticker POXEL.PA. It has been listed since 6 February 2015. In the fiscal year to 31 December 2024, it reported revenue of €6.6m and a net loss of €18.3m. At that date it held total assets of €14.9m and shareholders' equity of −€58.9m.
Poxel SA is a biopharmaceutical company, which engages in development of molecules for the potential treatment of type 2 diabetes. The company is headquartered in Lyon, Auvergne-Rhone-Alpes. The company went IPO on 2015-02-06. The firm develops drugs with a focus on Type 2 diabetes. The firm aims at developing drugs from preclinical to phase 2 clinical proof of concept. Its lead product, Imeglimin, is in clinical phase 2 study for Type 2 diabetes indication. A direct activator of AMPK for the treatment of Type 2 diabetes has started its preclinical development, and other projects in the research phase target diabetes and other metabolic diseases with small molecules that have a disease-modifying mechanism of action. Poxel SAS was spun out from Merck Serono. The firm cooperates with the Laboratory for Fundamental and Applied Bioenergetics, Sumitomo Dainippon Pharma, Joseph Fourier University and Department of Cell Physiology and Metabolism at the University of Geneva, Switzerland, among others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 6 Feb 2015
- Employees
- 44
- Website
- poxelpharma.com ↗
Leadership
Pay as last reported
- Ms. Sophie LapointeIndependent Chairman of the Board
- Mr. Nicolas TroucheChief Executive Officer, Director, since 2025
- Dr. Sebastien BolzeChief Operating Officer, Executive Vice President in charge of Project Management, Non Clinical and Manufacturing operations, since 2019
- Mr. Noah BeermanExecutive Vice President in charge of Business Development and President of Operations in the United States
- Dr. Pascale FouquerayExecutive Vice President, in charge of Clinical Development and Regulatory Affairs, since 2019
- Ms. Elizabeth WooSenior Vice President, Investor Relations, Public Relations and Corporate Communications
- Dr. Sophie BozecSenior Vice President in charge of R&D Pharmacology and Scientific Communication, since 2019
- Dr. David MollerChief Scientific Officer
- Ms. Sylvie BertrandVice President - Human Resources
- Mr. Quentin DurandChief Legal Officer and Head of Corporate Social Responsibility
- Mr. Alexandre BragadirDirector
- Mr. Amit KohliIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 60
- Environment
- 18
- Social
- 99
- Governance
- 63
- Energy emissions (scope 2)
- 1.78 t
- Value chain emissions (scope 3)
- 40 t
- Women in the workforce
- 69%
- Carbon reduction policy
- Yes
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Poxel SA has several strengths that contribute to its success in the market. Firstly, the company has a strong and experienced management team with deep knowledge of the pharmaceutical industry. This allows them to make informed and strategic decisions. Secondly, Poxel SA has a robust pipeline of innovative and potentially groundbreaking drugs, which can provide a competitive edge in the market. Additionally, the company has established strong relationships with key partners and collaborators, enabling them to effectively leverage resources and expertise.
Weaknesses
- While Poxel SA has many strengths, it also faces certain weaknesses that need to be addressed. One of the weaknesses is the company's heavy reliance on a limited number of products for revenue generation. This concentration of revenue creates a vulnerability for Poxel SA, as adverse events or market changes related to these products could significantly impact its financial performance. Moreover, Poxel SA has a relatively small market share compared to its competitors, which limits its bargaining power with suppliers.
Opportunities
- Poxel SA operates in an industry with several growth opportunities. Firstly, there is a rising global demand for innovative pharmaceuticals, especially in the field of metabolic disorders. Poxel SA can take advantage of this demand by leveraging its expertise and developing effective drugs to address this unmet need. Furthermore, the company can explore partnerships and collaborations to expand its market reach and penetrate new regions. Additionally, advancements in technology and research provide Poxel SA with the opportunity to develop more personalized and targeted therapies, leading to improved patient outcomes.
Threats
- Like any other company in the pharmaceutical industry, Poxel SA also faces threats that could impact its future growth and profitability. One of the major threats is the stringent regulatory environment, which can delay the approval and commercialization of new drugs. Additionally, the industry is highly competitive, with numerous companies vying for market share. This intensifies the need for Poxel SA to continuously innovate and differentiate its products. Economic downturns and fluctuations in currency exchange rates can also pose threats to the company's financial stability.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.